Nicholas Trpezanovski, Founder and Principal ConsultantNJT MedTech Solutions approaches commercialization with a “we and us” mentality, working alongside healthcare innovators instead of developing strategy at a distance.
Australia and New Zealand remain highly relationship-driven healthcare markets. Before a technology reaches formal approval pathways, healthcare organizations need confidence in how it fits within existing systems. NJT focuses on helping clients understand how healthcare systems are likely to evaluate and respond to a new innovation before formal processes begin. Conversations across clinical, procurement, operational, financial and healthcare administration stakeholders often uncover practical concerns, positioning challenges and adoption barriers that are not yet visible at the product level.
“We start with the path of least resistance,” says Nicholas Trpezanovski, founder and principal consultant. “Rather than pushing innovation/technology through the system, we identify where a technology is most likely to gain early acceptance and builds the approval pathway from there.”
Aligning Healthcare Systems Around Adoption
Commercialization starts with a simple question: does the technology address a genuine patient or healthcare-system need?
According to Nicholas, adoption becomes significantly more difficult when companies try to create demand around products that do not naturally align with clinical or operational realities. NJT’s role is not to manufacture demand but to determine whether a meaningful need exists and whether the healthcare environment is ready for adoption. In some cases, that process reveals a product may not yet have a clear place within the Australian healthcare system.
-
We start with the path of least resistance. By focusing first on where an innovation/technology is most likely to gain early receptiveness within the healthcare system, those early responses help shape the broader approval approach.
Once a technology demonstrates strong alignment, NJT focuses on building the evidence and stakeholder support needed for wider implementation. Through burden-of-disease analysis, health economics modelling and pilot implementations, the company helps healthcare organizations evaluate how technologies may influence patient care, operational efficiency and long-term cost outcomes before broader rollout decisions are made.
NJT also works closely with procurement leaders, clinicians, key opinion leaders and patient advocacy organizations connected to areas such as cancer, kidney disease and diabetes care. Those relationships help demonstrate genuine treatment gaps and unmet patient needs during approval processes.
Trust plays a central role throughout that process. For Nicholas, relationships are not simply a route to market. They are the foundation of the company’s reputation across Australia and parts of Asia.
The Invisible Drivers of Healthcare Adoption
One project involved an infection-control solution entering Australia that did not fit existing iodine, antibiotic or antiseptic classifications. Because the technology sat outside conventional healthcare definitions, there was no obvious approval category, procurement pathway or tender structure through which it could naturally progress.
Before hospitals could evaluate the product, NJT worked through discussions and presentations with health departments, pharmacy groups, nursing teams and procurement stakeholders. Those conversations helped establish that the technology was safe, non-toxic and genuinely separate from existing categories.
Supported by analysis and early hospital feedback, the solution eventually moved into usage across hospitals nationwide.
The experience reinforced an important lesson: a product can be clinically valuable and still struggle if healthcare organizations do not understand where it fits. NJT helped the system understand the innovation before asking it to approve it.
Nicholas is seeing AI-enabled functionality rapidly become an expectation across healthcare technology environments, particularly in digital health, app-based technologies and diagnostic platforms. In many cases, healthcare organizations are no longer asking whether AI is relevant. They are asking how it is being used.
For NJT, healthcare transformation begins with strong technology, but it only moves forward when the right people understand it, trust it and see where it fits. NJT’s relationship-driven approach has earned the company recognition from Healthcare Business Review APAC as one of the Top Healthcare Transformation Services Providers in APAC 2026.
What Health Care Transformation Requires in APAC
Health care transformation in APAC is no longer shaped only by the quality of a new technology. Hospitals, public health systems and private providers need proof that an innovation can enter care settings without creating avoidable friction, cost pressure or adoption risk. For executives evaluating health care transformation services, the real test is whether a partner can move a product from promise to accepted use inside systems where clinical value, budget control, patient need and stakeholder confidence all matter at once.
The challenge is especially sharp in Australia and New Zealand, where adoption often depends on trust before a transaction. A strong device, digital health tool or care model can still slow down if it enters the wrong pathway, reaches the wrong audience or lacks the evidence needed for decision-makers to act. Procurement is rarely a single gate. It can involve clinicians, department leaders, finance teams, executives, public agencies and patient groups, each viewing the same innovation through a different lens. A capable transformation partner must understand how those viewpoints interact before the formal approval process begins.
The most effective support begins by testing fit. Not every overseas technology, research-led idea or early-stage health solution has a clear place in the local system. Executives should value partners willing to examine whether a genuine care need exists, whether the solution addresses that need cleanly and whether the market pathway is realistic. This protects vendors from forcing demand where the system has little reason to change, while helping promising innovations find the right route into practice.
Evidence also matters more than enthusiasm. Health systems facing budget pressure need cost-benefit logic, economic modeling, pilot data and practical proof from clinical settings. A transformation partner should be able to translate an innovation’s promise into a case that shows how it can reduce burden, improve efficiency, support safer care or justify upfront expense over time. That work cannot be generic. It must be shaped around the disease state, setting, approval pathway and procurement context in which the solution will be judged.
Relationship management is equally important. Informal discussion can reveal concerns that a formal submission may miss, from safety questions to workflow fit or committee review requirements. The strongest partners know when to start conversations early, how to position unfamiliar technologies and when patient advocacy can strengthen awareness around an unmet need. In a region where AI-enabled tools, diagnostic platforms and digital health capabilities are gaining attention, this human navigation remains essential.
NJT MedTech Solutions stands out for organizations entering or scaling in the Australian and New Zealand healthcare market. It brings together commercialization guidance, corporate and government engagement, procurement pathway support, tender assistance and ANZ market entry expertise without separating strategy from adoption. Its approach is grounded in partnership, stakeholder access, patient-need validation and evidence building, including health economics, pilot support and cost-benefit work. For executives that need more than advice, NJT MedTech Solutions is a strong choice because it helps innovations move through the people, proof and approval pathways that determine whether health care transformation actually reaches patients.
...Read more
